Zimmer Biomet Holdings Inc Dossier
Qualitative Analysis
Business overview
Zimmer Biomet Holdings, Inc. is a global medical technology leader specializing in musculoskeletal healthcare. Founded in 1927 and headquartered in Warsaw, Indiana, the company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip implants, sports medicine, biologics, extremities, trauma, craniomaxillofacial, and thoracic products. Zimmer Biomet also offers a comprehensive suite of integrated digital and robotic technologies, such as the ROSA Robot and the ZBEdge Platform, which leverage artificial intelligence and data analytics to assist surgeons and optimize patient outcomes.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the U.S. commercial organization to a predominantly direct and specialized sales channel to drive more durable and consistent long-term growth.
Expected impact: Tempers 2026 sales guidance due to short-term disruption risks, but is projected to solidify Zimmer Biomet's position as a market leader and drive durable long-term growth.
Targeting the rapidly growing ASC market through dedicated sales channels, strategic partnerships, and the ZBX ASC Solutions offering.
Expected impact: Aims to capture market share as orthopedic surgeries increasingly migrate from traditional hospital settings to ASCs.
Expanding the S.E.T. business segment through organic product launches and strategic acquisitions like Paragon 28.
Expected impact: Targeting double-digit growth in S.E.T. to shift the portfolio mix toward faster-growing categories.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire semi- and fully autonomous robotic technologies to expand Zimmer Biomet's flagship ROSA Robotics platform and broad suite of navigation and enabling technologies.
Financial impact: Anticipated to be neutral to adjusted earnings per share in 2025, 2026 and 2027, and accretive in 2028 and beyond.
To expand Zimmer Biomet's presence in the high-growth foot and ankle market with new offerings in fracture, trauma, deformity correction, and joint replacement.
Financial impact: Expected to contribute approximately 100 basis points to reported sales growth in 2026 before being reflected in organic growth in April 2026.
Strategic Partnerships
Zimmer Biomet will distribute Getinge's Operating Room (OR) capital products to its Ambulatory Surgery Center (ASC) customers, creating a turnkey solution that combines Getinge's infection control and surgical portfolio with Zimmer Biomet's implants and robotics.
Terms: Not disclosed; implemented in phases starting in the U.S.
A multi-year strategic partnership designed to accelerate new technologies and approaches that improve joint replacement, bone healing, and mobility, while collaborating on technical training and workforce development.
Terms: Not disclosed